Elotuzumab (anti-SLAMF7)

目录号：A2034         批次号: A203402

打印

Elotuzumab（anti-SLAMF7、BMS-901608、PDL063、HuLuc63）是一种人源化单克隆抗体，可结合人类信号淋巴细胞激活分子 F7（hSLAMF7，也称为 CS1、CD319 或 CRACC）。Elotuzumab 具有双重作用机制，包括直接激活自然杀伤 (NK) 细胞和诱导 NK 细胞介导的抗体依赖性细胞毒性。

抗体信息

CAS号 915296-00-3
配制 PBS Buffer, PH 7.4
推荐同型对照 Human IgG1, κ
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 10.96 mg/ml
内毒素 ＜1EU/mg

Elotuzumab (anti-SLAMF7)在文献中得到引用

Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy [ Nat Cancer, 2025, 10.1038/s43018-025-00927-0] PubMed: 40097658
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma [ Nat Commun, 2024, 15(1):1367] PubMed: 38355622
CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy [ J Cancer, 2024, 15(10):3065-3075] PubMed: 38706917
CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy [ J Cancer, 2024, 15(10):3065-3075] PubMed: 38706917

禁止用于人体及治疗！